A phase I/II safety, tolerability, and pharmacokinetic study of high dose lopinavir/ritonavir with or without saquinavir in HIV-infected pediatric subjects previously treated with protease inhibitors

Trial Profile

A phase I/II safety, tolerability, and pharmacokinetic study of high dose lopinavir/ritonavir with or without saquinavir in HIV-infected pediatric subjects previously treated with protease inhibitors

Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 May 2012

At a glance

  • Drugs Lopinavir/ritonavir (Primary) ; Saquinavir (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 03 Apr 2012 Actual patient number is 26 according to ClinicalTrials.gov.
    • 28 Sep 2008 The actual trial end date is 1 Dec 2006 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top